Pharmacy & PharmacologyPharmacy & PharmacologyФармация и фармакология2307-92662413-2241Eco-Vector11165710.19163/2307-9266-2020-8-6-392-404ArticlesСтатьиReview ArticlePharmacogenetic bases of individual sensitivity and personalized administration of antiplatelet therapy in different ethnic groupsФармакогенетические основы индивидуальной чувствительности и персонализированного назначения антиагрегантной терапии в различных этнических группахhttps://orcid.org/0000-0003-3278-2556KantemirovaBela I.КантемироваБэла Исмаиловна
Russian Federation

Doctor of Sciences (Medicine), Associate Professor, Professor of the Department of Pharmacology

доктор медицинских наук, доцент, профессор кафедры фармакологии

belakantemirova@rambler.ruhttps://orcid.org/0000-0002-9126-1171OrlovaEkaterina A.ОрловаЕкатерина Алексеевна
Russian Federation

Candidate of Sciences (Medicine), Associate Professor, the Head of the Department of Pharmacology

кандидат медицинских наук, доцент, заведующая кафедрой фармакологии

eorlova56@mail.ruhttps://orcid.org/0000-0001-8299-6582PoluninaOlga S.ПолунинаОльга Сергеевна
Russian Federation

Doctor of Sciences (Medicine), Professor, Head of the Department of Internal Diseases of the Pediatric Faculty

доктор медицинских наук, профессор, заведующая кафедрой внутренних болезней педиатрического факультета

admed@yandex.ruhttps://orcid.org/0000-0001-8884-1178ChernyshevaElena N.ЧернышеваЕлена Николаевна
Russian Federation

Doctor of Sciences (Medicine), Associate Professor, Head of the Department of Cardiology of the Faculty of Postgraduate Training

д.м.н., доцент, заведующая кафедрой кардиологии факультета последипломной подготовки Федерального государственного бюджетного образовательного учреждения высшего образования

lena.chernysheva@inbox.ruhttps://orcid.org/0000-0001-7374-2660AbdullaevMusalitdin A.АбдуллаевМусалитдин Абсаламович
Russian Federation

postgraduate student of the Department of Pharmacology

аспирант кафедры фармакологии

abdullaev-musalitdin@mail.ruhttps://orcid.org/0000-0002-5195-4301SychevDmitry A.СычевДмитрий Алексеевич
Russian Federation

Doctor of Sciences (Medicine), Professor, Rector

доктор медицинских наук, профессор, ректор

dimasychev@mail.ruAstrakhan State Medical UniversityФГБОУ ВО «Астраханский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииRussian Medical Academy of Continuing Professional Education (RMA CPE)ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Министерства здравоохранения Российской Федерации1512202086VOL 8, NO6 (2020)ТОМ 8, №6 (2020)39240406102022Copyright ©; 2020, Kantemirova B.I., Orlova E.A., Polunina O.S., Chernysheva E.N., Abdullaev M.A., Sychev D.A.Copyright ©; 2020, Кантемирова Б.И., Орлова Е.А., Полунина О.С., Чернышева Е.Н., Абдуллаев М.А., Сычев Д.А.Copyright ©; 2020,2020Kantemirova B.I., Orlova E.A., Polunina O.S., Chernysheva E.N., Abdullaev M.A., Sychev D.A.Кантемирова Б.И., Орлова Е.А., Полунина О.С., Чернышева Е.Н., Абдуллаев М.А., Сычев Д.А.https://creativecommons.org/licenses/by/4.0https://journals.eco-vector.com/2307-9266/article/view/111657

Cardiovascular diseases (CVDs) are the leading cause of disability and mortality worldwide. Increased thrombosis is the trigger point for the development of various CVDs and their complications, and therefore, therapy with P2Y12-receptor inhibitors is always pathogenetically justified and vital. However, according to the various data, 10-25% of patients treated with clopidogrel have “resistance” to antiplatelet therapy. The causes for the formation of resistance are still not clear. There is no generally accepted, standard methodology for determining resistance to antiplatelet agents. In addition, there are no methodological approaches to identify the patients with resistance to antiplatelet drugs, and standardized schemes for correcting a low sensitivity to these drugs.

The aim of this review was to summarize the available results of foreign and domestic studies devoted to the investigation of the effectiveness and safety problems of antiplatelet drugs administration from the point of view of the genetic predisposition to changes in their metabolism.

Materials and methods. For the review, the following information from scientific literature represented in open and accessible sources for the period of 1996-2020, was used: pharmgkb.org, PubMed, Scopus, Web of Science Core Collection, Elibrary. Search queries – “Genetic features+antiplatelet therapy+ethnic groups”, “CYP2C19+clopidogrel+antiplatelet therapy effectiveness”; “Stent retrombosis+CYP2C19 polymorphism+ residual platelet reactivity” and “CYP2C19 polymorphism+ethnic groups+clopidogrel resistance” in both Russian and English equivalents. All these data are placed in electronic databases.

Results. Currently, the problem of the resistance formation to antiplatelet drugs is studied insufficiently. The best thought-out issue is the research of the effect of the polymorphic alleles carriage of the CYP2C19 gene on the residual platelet reactivity in the patients administrated with dual antiplatelet treatment, including clopidogrel. In general, the analysis of open literature sources indicates the presence of a statistically significant association between the carrier of slow alleles of the CYP2C19 gene and the residual platelet reactivity, clinically manifested by thrombosis and adverse cardiovascular events. The occurrence frequency of polymorphic carriage of the CYP2C19 gene varies in different ethnic groups, so it cannot be extrapolated to individual subjects, peculiar in the ethnic diversity.

Conclusion. To develop preventive and predictive measures aimed at overcoming resistance to antiplatelet agents, as well as working out methodological approaches to personalized prescribtion of this group drugs, a further investigation with the expansion of the search for causes and the study of the other genes participation of the cytochrome P450 system, is required.

Сердечно-сосудистые заболевания (ССЗ) являются ведущей причиной инвалидности и смертности населения во всем мире. Повышенное тромбообразование является пусковым моментом развития различных ССЗ и их осложнений, в связи с чем, терапия ингибиторами P2Y12-рецепторов всегда является патогенетически обоснованной и жизненно необходимой. Однако, по разным данным, у 10-25% пациентов, получающих клопидогрел, отмечается «резистентность» к антиагрегантной терапии. Причины формирования резистентности до сих пор не ясны. Общепризнанной, стандартной методики определения резистентности к антиагрегантам не существует. Кроме того, нет методологических подходов по выявлению пациентов с невосприимчивостью к антиагрегационным препаратам и стандартизированных схем коррекции низкой чувствительности к ним.

Цель. Целью написания данного обзора было резюмировать имеющиеся результаты зарубежных и отечественных исследований, посвященных изучению вопросов эффективности и безопасности назначения антитромбоцитарных препаратов с позиции генетической предрасположенности к изменению их метаболизма.

Материалы и методы. Для обзора использовали сведения научной литературы из открытых и доступных источников за период 1996–2020 гг., размещенных в электронных базах данных: pharmgkb.org; PubMed; Scopus; Web of Science Core Collection; Elibrary. Поисковые запросы – «генетические особенности+антиагрегационная терапия+этнические группы», «CYP2C19+клопидогрел+эффективность антитромбоцитарной терапии»; «ретромбоз стента+полиморфизм CYP2C19+ остаточная реактивность тромбоцитов» и «полиморфизм CYP2C19+этнические группы+резистентность к клопидогрелу» как в русском, так и английском эквиваленте.

Результаты. Проблема формирования резистентности к антиагрегационным препаратам в настоящее время изучена недостаточно. Наиболее проработанным вопросом является изучение влияния носительства полиморфных аллелей гена CYP2C19 на остаточную реактивность тромбоцитов, у пациентов получающих двойную антиагрегационную терапию, включающую клопидогрел. Анализ открытых литературных источников, в целом, свидетельствует о наличии статистически значимой ассоциативной связи между носительством медленных аллелей гена CYP2C19 и остаточной реактивностью тромбоцитов, клинически проявляющуюся тромбозом и неблагоприятными сердечно-сосудистыми событиями. Частота встречаемости полиморфного носительства гена CYP2C19 варьирует в разных этнических группах, поэтому не может быть экстраполирована на отдельные субъекты, отличающиеся этническим разнообразием.

Заключение. Для разработки превентивных и предиктивных мер по преодолению резистентности к антиагрегантам, а также методологических подходов к персонализированному назначению препаратов этой группы, требуются дальнейшие исследования, с расширением поиска причин и изучением участия других генов системы цитохрома Р450.

antiplatelet agentsclopidogrelpharmacogeneticsethnic groupsresistance to antiplatelet therapyантиагрегантыклопидогрелфармакогенетикаэтнические группырезистентность к антиагрегантной терапииIskakov YeB. Epidemiology of cardiovascular diseases. Medicine and ecology. 2017;2:19–28. RussianИскаков Е.Б. Эпидемиология сердечно-сосудистых заболеваний // Медицина и экология. – 2017. – №2. – С. 19–28.Ivanov DO, Orel VI, Aleksandrovich YuS, Pshenisnov KV, Lomovceva RH. Diseases of the cardiovascular system as the leading cause of death in russian federation: ways of problem solution. Medicine and Organization of Health Care. 2019;4(2):4–12. RussianИванов Д.О., Орел В.И., Александрович Ю.С., Пшениснов К.В., Ломовцева Р.Х. Заболевания сердечно-сосудистой системы как причина смертности в Российской Федерации: пути решения проблемы // Медицина и организация здравоохранения. – 2019. – Т. 4. – №2. – С. 4–11.Mărginean A, Bănescu C, Moldovan V, Scridon A, Mărginean M, Bălaşa R, Maier S, Ţăruşi M, Dobreanu M. The Impact of CYP2C19 Loss-of-Function Polymorphisms, Clinical, and Demographic Variables on Platelet Response to Clopidogrel Evaluated Using Impedance Aggregometry. Clin Appl Thromb Hemost. 2017 Apr;23(3):255–265. DOI: 10.1177/1076029616629211.Mărginean A., Bănescu C., Moldovan V., Scridon A., Mărginean M., Bălaşa R., Maier S., Ţăruşi M., Dobreanu M. The Impact of CYP2C19 Loss-of-Function Polymorphisms, Clinical, and Demographic Variables on Platelet Response to Clopidogrel Evaluated Using Impedance Aggregometry // Clin Appl Thromb Hemost. – 2017. – Vol. 23. – No.3. – P. 255–265. DOI: 10.1177/1076029616629211.Mesitskaia DF, Nikitina IuM, Kopylov FIu, Nesterova SG. Resistance to clopidogrel: do we know everything? Kardiologiya i Serdechno-Sosudistaya Khirurgiya. 2013;6(1):27–32.Меситская Д.Ф., Никитина Ю.М., Копылов Ф.Ю., Нестерова С.Г. Резистентность к клопидогрелу: все ли мы знаем? // Кардиология и сердечно-сосудистая хирургия. – 2013. Т. 6. – №1. – С. 27–32.Lewis JP, Riaz M, Xie S, Polekhina G, Wolfe R, Nelson M, Tonkin AM, Reid CM, Murray AM, McNeil JJ, Shuldiner AR, Lacaze P. Genetic Variation in PEAR1, Cardiovascular Outcomes and Effects of Aspirin in a Healthy Elderly Population. Clin Pharmacol Ther. 2020 Dec;108(6):1289–1298. DOI: 10.1002/cpt.1959.Lewis J.P., Riaz M., Xie S., Polekhina G., Wolfe R., Nelson M., Tonkin A.M., Reid C.M., Murray A.M., McNeil J.J., Shuldiner A.R., Lacaze P. Genetic Variation in PEAR1, Cardiovascular Outcomes and Effects of Aspirin in a Healthy Elderly Population // Clin Pharmacol Ther. – 2020. – Vol. 108. – No.6. – P. 1289–1298. DOI: 10.1002/cpt.1959.Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003 Mar 19;41(6):961–5. DOI: 10.1016/s0735-1097(02)03014-0.Gum P.A., Kottke-Marchant K., Welsh P.A., White J., Topol E.J. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease // J Am Coll Cardiol. – 2003. – Vol. 41. – No.6. – P. 961–965. DOI: 10.1016/s0735-1097(02)03014-0.Kurcheva N.P., Mirzaev K.B., Sychev D.A. A multifactorial algorithm to predict on-clopidogrel platelet reactivity as a potential way to improve the efficacy and safety of antiplatelet therapy. Pharmacogenetics and Pharmacogenomics. 2015;(2):29–32. RussianКурчева Н.П., Мирзаев К.Б., Сычёв Д.А. Многофакторный алгоритм прогнозирования антиагрегантного действия клопидогрела, как потенциальный способ повышения эффективности и безопасности антиагрегантной терапии // Фармакогенетика и Фармакогеномика. – 2015. – №2. – С. 29 –32.Gershlick AH, Price MJ. Full Revascularization in the Patient With ST-Segment Elevation Myocardial Infarction: The Story So Far. J Am Coll Cardiol. 2019 Dec 3;74(22):2724–2727. DOI: 10.1016/j.jacc.2019.10.022.Gershlick A.H., Price M.J. Full Revascularization in the Patient With ST-Segment Elevation Myocardial Infarction: The Story So Far // J Am Coll Cardiol. – 2019. – Vol. 74. – No.22. – P. 2724–2727. DOI: 10.1016/j.jacc.2019.10.022.Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009 Jan 22;360(4):354–62. DOI: 10.1056/NEJMoa0809171.Mega J.L., Close S.L., Wiviott S.D., Shen L., Hockett R.D., Brandt J.T., Walker J.R., Antman E.M., Macias W., Braunwald E., Sabatine M.S. Cytochrome p-450 polymorphisms and response to clopidogrel // N Engl J Med. – 2009. – Vol. 360. – No.4. – P .354–362. DOI: 10.1056/NEJMoa0809171.Mirzaev K.B., Sychev D.A., Andreev D.A. GENETICS OF CLOPIDOGREL RESISTANCE: RECENT DATA. Russian Journal of Cardiology. 2015;(10):92–98. DOI: 10.15829/1560-4071-2015-10-92-98. RussianМирзаев К.Б., Сычев Д.А., Андреев Д.А. Генетические основы резистентности к клопидогрелу: современное состояние проблемы // Российский кардиологический журнал. – 2015. – Т. 10. – №126. – С. 92–98. DOI: 10.15829/1560-4071-2015-10-92-98.Saiz-Rodríguez M, Romero-Palacián D, Villalobos-Vilda C, Caniego JL, Belmonte C, Koller D, Bárcena E, Talegón M, Abad-Santos F. Influence of CYP2C19 Phenotype on the Effect of Clopidogrel in Patients Undergoing a Percutaneous Neurointervention Procedure. Clin Pharmacol Ther. 2019 Mar;105(3):661–671. DOI: 10.1002/cpt.1067.Saiz-Rodríguez M., Romero-Palacián D., Villalobos-Vilda C., Caniego J.L., Belmonte C., Koller D., Bárcena E., Talegón M., Abad-Santos F. Influence of CYP2C19 Phenotype on the Effect of Clopidogrel in Patients Undergoing a Percutaneous Neurointervention Procedure // Clin Pharmacol Ther. – 2019. – Vol. 105. – No.3. – P. 661–671. DOI: 10.1002/cpt.1067.Grabuzdov AM, Shuev GN, Sulejmanov SSh, Ryzhikova KA, Sychyov DA. Sravnenie chastoty vstrechaemosti odnonukleotidnogo varianta CYP3A5*3 v etnicheskih gruppah russkih i nanajcev. Pharmacogenetics and Pharmacogenomics. 2017;2:48–49. RussianГрабуздов А.М., Шуев Г.Н., Сулейманов С.Ш., Рыжикова К.А., Сычёв Д.А. Сравнение частоты встречаемости однонуклеотидного варианта CYP3A5*3 в этнических группах русских и нанайцев // Фармакогенетика и Фармакогеномика. – 2017. – №2. – С. 48–49.Mejin M, Tiong WN, Lai LY, Tiong LL, Bujang AM, Hwang SS, Ong TK, Fong AY. CYP2C19 genotypes and their impact on clopidogrel responsiveness in percutaneous coronary intervention. Int J Clin Pharm. 2013 Aug;35(4):621–8. DOI: 10.1007/s11096-013-9783-y.Melissa M., Wen Ni T, Lana Yin Hui Lai, Lee Len Tiong, Adam Mohamad Bujang et all. CYP2C19 genotypes and their impact on clopidogrel responsiveness in percutaneous coronary intervention // International Journal of Clinical Pharmacy. – 2013. – Vol. 35. – P. 621–628. DOI: 10.1007/s11096-013-9783-yMirzaev KB, Sychev DA, Ryzhikova KA, Konova OD, Mammaev SN, Gafurov DM, Shuev GN, Grishina EA, Sozaeva ZA. Genetic Polymorphisms of Cytochrome P450 Enzymes and Transport Proteins in a Russian Population and Three Ethnic Groups of Dagestan. Genet Test Mol Biomarkers. 2017 Dec;21(12):747–753. DOI: 10.1089/gtmb.2017.0036.Mirzaev K.B., Sychev D.A., Ryzhikova K.A., Konova O.D., Mammaev S.N., Gafurov D.M., Shuev G.N., Grishina E.A., Sozaeva Z.A. Genetic Polymorphisms of Cytochrome P450 Enzymes and Transport Proteins in a Russian Population and Three Ethnic Groups of Dagestan // Genet Test Mol Biomarkers. – 2017. – Vol. 21. – No.12. – P. 747–753. DOI: 10.1089/gtmb.2017.0036.Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, Stillabower ME, Aragon JR, Kandzari DE, Stinis CT, Lee MS, Manoukian SV, Cannon CP, Schork NJ, Topol EJ; GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011 Mar 16;305(11):1097–105. DOI: 10.1001/jama.2011.290.Price M.J., Berger P.B., Teirstein P.S., Tanguay J.F., Angiolillo D.J., Spriggs D., Puri S., Robbins M., Garratt K.N., Bertrand O.F., Stillabower M.E., Aragon J.R., Kandzari D.E., Stinis C.T., Lee M.S., Manoukian S.V., Cannon C.P., Schork N.J., Topol E.J.; GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial // JAMA. – 2011. – Vol. 305. – No.11. – P. 1097–1105. DOI: 10.1001/jama.2011.290.Kuliczkowski W, Witkowski A, Polonski L, Watala C, Filipiak K, Budaj A, Golanski J, Sitkiewicz D, Pregowski J, Gorski J, Zembala M, Opolski G, Huber K, Arnesen H, Kristensen SD, De Caterina R. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J. 2009 Feb;30(4):426–35. DOI: 10.1093/eurheartj/ehn562.Kuliczkowski W., Witkowski A., Polonski L., Watala C., Filipiak K., Budaj A., Golanski J., Sitkiewicz D., Pregowski J., Gorski J., Zembala M., Opolski G., Huber K., Arnesen H., Kristensen S.D., De Caterina R. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology // Eur Heart J. – 2009. – Vol. 30. – No.4. – P. 426–435. DOI: 10.1093/eurheartj/ehn562.17. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002;41(12):913–58. DOI: 10.2165/00003088-200241120-00002.Desta Z., Zhao X., Shin J.G., Flockhart D.A. Clinical significance of the cytochrome P450 2C19 genetic polymorphism // Clin Pharmacokinet. – 2002. – Vol. 41. – No.12. – P. 913–958. DOI: 10.2165/00003088-200241120-00002.Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol. 2001;41:815–50. DOI: 10.1146/annurev.pharmtox.41.1.815.Xie H.G., Kim R.B., Wood A.J., Stein C.M. Molecular basis of ethnic differences in drug disposition and response // Annu Rev Pharmacol Toxicol. – 2001. – No.41. – P. 815–850. DOI: 10.1146/annurev.pharmtox.41.1.815.Zand N, Tajik N, Moghaddam AS, Milanian I. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population. Clin Exp Pharmacol Physiol. 2007 Jan-Feb;34(1–2):102–5. DOI: 10.1111/j.1440-1681.2007.04538.x.Zand N., Tajik N., Moghaddam A.S., Milanian I. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population // Clin Exp Pharmacol Physiol. – 2007. – Vol. 34. – No.1–2. – P. 102–105. DOI: 10.1111/j.1440-1681.2007.04538.x.Sorich MJ, Rowland A, McKinnon RA, Wiese MD. CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis. Circ Cardiovasc Genet. 2014 Dec;7(6):895–902. DOI: 10.1161/CIRCGENETICS.114.000669.Sorich M.J., Rowland A., McKinnon R.A., Wiese M.D. CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis // Circ Cardiovasc Genet. – 2014. – Vol. 7. – No.6. – P. 895–902. DOI: 10.1161/CIRCGENETICS.114.000669.Verma SS, Bergmeijer TO, Gong L, Reny JL, Lewis JP, Mitchell BD, Alexopoulos D, Aradi D, Altman RB, Bliden K, Bradford Y, Campo G, Chang K, Cleator JH, Déry JP, Dridi NP, Fernandez-Cadenas I, Fontana P, Gawaz M, Geisler T, Gensini GF, Giusti B, Gurbel PA, Hochholzer W, Holmvang L, Kim EY, Kim HS, Marcucci R, Montaner J, Backman JD, Pakyz RE, Roden DM, Schaeffeler E, Schwab M, Shin JG, Siller-Matula JM, Ten Berg JM, Trenk D, Valgimigli M, Wallace J, Wen MS, Kubo M, Lee MTM, Whaley R, Winter S, Klein TE, Shuldiner AR, Ritchie MD; ICPC Investigators. Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium. Clin Pharmacol Ther. 2020 Nov;108(5):1067–1077. DOI: 10.1002/cpt.1911.Verma S.S., Bergmeijer T.O., Gong L., Reny J.L., Lewis J.P., Mitchell B.D., Alexopoulos D., Aradi D., Altman R.B., Bliden K., Bradford Y., Campo G., Chang K., Cleator J.H., Déry J.P., Dridi N.P., Fernandez-Cadenas I., Fontana P., Gawaz M., Geisler T., Gensini G.F., Giusti B., Gurbel P.A., Hochholzer W., Holmvang L., Kim E.Y., Kim H.S., Marcucci R., Montaner J., Backman J.D., Pakyz R.E., Roden D.M., Schaeffeler E., Schwab M., Shin J.G., Siller-Matula J.M., Ten Berg J.M., Trenk D., Valgimigli M., Wallace J., Wen M.S., Kubo M., Lee M.T.M., Whaley R., Winter S., Klein T.E., Shuldiner A.R., Ritchie M.D.; ICPC Investigators. Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium // Clin Pharmacol Ther. – 2020. – Vol. 108. – No.5. – P. 1067–1077. DOI: 10.1002/cpt.1911.Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, Payot L, Brugier D, Cayla G, Beygui F, Bensimon G, Funck-Brentano C, Montalescot G. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009 Jan 24;373(9660):309–17. DOI: 10.1016/S0140-6736(08)61845-0.Collet J.P., Hulot J.S., Pena A., Villard E., Esteve J.B., Silvain J., Payot L., Brugier D., Cayla G., Beygui F., Bensimon G., Funck-Brentano C., Montalescot G. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study // Lancet. – 2009. – Vol. 373. – No.9660. – P. 309–317. DOI: 10.1016/S0140-6736(08)61845-0.Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, Steg PG, Ferrières J, Danchin N, Becquemont L; French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009 Jan 22;360(4):363–75. DOI: 10.1056/NEJMoa0808227.Simon T., Verstuyft C., Mary-Krause M., Quteineh L., Drouet E., Méneveau N., Steg P.G., Ferrières J., Danchin N., Becquemont L.; French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events // N Engl J Med. – 2009. – Vol. 360. – No.4. – P. 363–375. DOI: 10.1056/NEJMoa0808227.Sibbing D, Stegherr J, Latz W, Koch W, Mehilli J, Dörrler K, Morath T, Schömig A, Kastrati A, von Beckerath N. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J. 2009 Apr;30(8):916–22. DOI: 10.1093/eurheartj/ehp041.Sibbing D., Stegherr J., Latz W., Koch W., Mehilli J., Dörrler K., Morath T., Schömig A., Kastrati A., von Beckerath N. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention // Eur Heart J. – 2009. – Vol. 30. – No.8. – P. 916–22. DOI: 10.1093/eurheartj/ehp041.Mega JL, Close SL, Wiviott SD, Shen L, Walker JR, Simon T, Antman EM, Braunwald E, Sabatine MS. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet. 2010 Oct 16;376(9749):1312–9. DOI: 10.1016/S0140-6736(10)61273-1.Mega J.L., Close S.L., Wiviott S.D., Shen L., Walker J.R., Simon T., Antman E.M., Braunwald E., Sabatine M.S. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis // Lancet. – 2010. – Vol. 376. – No.9749. – P. 1312–1319. DOI: 10.1016/S0140-6736(10)61273-1.Zhang HZ, Kim MH, Guo LZ, Serebruany V. CYP2C19 but not CYP2B6, CYP3A4, CYP3A5, ABCB1, PON1 or P2Y12 genetic polymorphism impacts antiplatelet response after clopidogrel in Koreans. Blood Coagul Fibrinolysis. 2017 Jan;28(1):56–61. DOI: 10.1097/MBC.0000000000000536.Zhang H.Z., Kim M.H., Guo L.Z., Serebruany V. CYP2C19 but not CYP2B6, CYP3A4, CYP3A5, ABCB1, PON1 or P2Y12 genetic polymorphism impacts antiplatelet response after clopidogrel in Koreans // Blood Coagul Fibrinolysis. – 2017. – Vol. 28. – No.1. – P. 56–61. DOI: 10.1097/MBC.0000000000000536.Teixeira, R., Grazina, M., Monteiro, P., Soares, F., Lourenço, M. and Pêgo, G. (2012) CYP2C19 (+ or –)*2/(+ or –)*17 Diplotypes: Prognostic impactson patients with acute coronary syndrome. World Journal of Cardiovascular Diseases. 2012;2:260–268. DOI: 10.4236/wjcd.2012.24041.Rogério T., Manuela G., Pedro M., Francisco S., Margarida L., et al. CYP2C19 (+ or －)*2/(+ or －)*17 Diplotypes: Prognostic impactson patients with acute coronary syndrome // World Journal of Cardiovascular Diseases. – 2012. – Vol. 2. – No.4. – 9 pp. DOI: 10.4236/wjcd.2012.24041Taubert D, von Beckerath N, Grimberg G, Lazar A, Jung N, Goeser T, Kastrati A, Schömig A, Schömig E. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther. 2006 Nov;80(5):486–501. DOI: 10.1016/j.clpt.2006.07.007.Taubert D., von Beckerath N., Grimberg G., Lazar A., Jung N., Goeser T., Kastrati A., Schömig A., Schömig E. Impact of P-glycoprotein on clopidogrel absorption // Clin Pharmacol Ther. – 2006. – Vol. 80. – No.5. – P. 486–501. DOI: 10.1016/j.clpt.2006.07.007.Miura G, Ariyoshi N, Sato Y, Yamaguchi H, Iwata Y, Fujimoto Y, Kobayashi Y, Ishii I. Genetic and non-genetic factors responsible for antiplatelet effects of clopidogrel in Japanese patients undergoing coronary stent implantation: an algorithm to predict on-clopidogrel platelet reactivity. Thromb Res. 2014 Oct;134(4):877–83. DOI: 10.1016/j.thromres.2014.07.018.Miura G., Ariyoshi N., Sato Y., Yamaguchi H., Iwata Y., Fujimoto Y., Kobayashi Y., Ishii I. Genetic and non-genetic factors responsible for antiplatelet effects of clopidogrel in Japanese patients undergoing coronary stent implantation: an algorithm to predict on-clopidogrel platelet reactivity // Thromb Res. – 2014. – Vol. 134. – No.4. – P. 877–883. DOI: 10.1016/j.thromres.2014.07.018.Jiang M, You JH. CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients: a decision analysis. Pharmacogenet Genomics. 2015 Dec;25(12):609–17. DOI: 10.1097/FPC.0000000000000177.Jiang M., You J.H. CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients: a decision analysis // Pharmacogenet Genomics. – 2015. – Vol. 25. – No.12. – P. 609–617. DOI: 10.1097/FPC.0000000000000177.Hokimoto S, Akasaka T, Tabata N, Arima Y, Tsujita K, Sakamoto K, Kaikita K, Morita K, Kumagae N, Yamamoto E, Oniki K, Nakagawa K, Ogawa H. Impact of esomeprazole on platelet reactivity and clinical outcome according to CYP2C19 genotype in coronary heart disease patients during dual antiplatelet therapy. Thromb Res. 2015 Jun;135(6):1081–6. DOI: 10.1016/j.thromres.2015.03.033.Hokimoto S., Akasaka T., Tabata N., Arima Y., Tsujita K., Sakamoto K., Kaikita K., Morita K., Kumagae N., Yamamoto E., Oniki K., Nakagawa K., Ogawa H. Impact of esomeprazole on platelet reactivity and clinical outcome according to CYP2C19 genotype in coronary heart disease patients during dual antiplatelet therapy // Thromb Res. – 2015. – Vol. 135. – No.6. – P. 1081–-1086. DOI: 10.1016/j.thromres.2015.03.033.Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, Klein TE, Sabatine MS, Johnson JA, Shuldiner AR; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013 Sep;94(3):317–23. DOI: 10.1038/clpt.2013.105.Scott S.A., Sangkuhl K., Stein C.M., Hulot J.S., Mega J.L., Roden D.M., Klein T.E., Sabatine M.S., Johnson J.A., Shuldiner A.R.; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update // Clin Pharmacol Ther. – 2013. – Vol. 94. – No.3. – P. 317–323. DOI: 10.1038/clpt.2013.105.Jang JS, Cho KI, Jin HY, Seo JS, Yang TH, Kim DK, Kim DS, Seol SH, Kim DI, Kim BH, Park YH, Je HG, Jeong YH, Lee SW. Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel. Am J Cardiol. 2012 Aug 15;110(4):502–8. DOI: 10.1016/j.amjcard.2012.04.020.Jang J.S., Cho K.I., Jin H.Y., Seo J.S., Yang T.H., Kim D.K., Kim D.S., Seol S.H., Kim D.I., Kim B.H., Park Y.H., Je H.G., Jeong Y.H., Lee S.W. Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel // Am J Cardiol. – 2012. – Vol. 110. – No.4. – P. 502–508. DOI: 10.1016/j.amjcard.2012.04.020.Tang XF, Wang J, Zhang JH, Meng XM, Xu B, Qiao SB, Wu YJ, Chen J, Wu Y, Chen JL, Gao RL, Yuan JQ, Yang YJ. Effect of the CYP2C19 2 and 3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention. Eur J Clin Pharmacol. 2013 May;69(5):1103–12. DOI: 10.1007/s00228-012-1446-8.Tang X.F., Wang J., Zhang J.H., Meng X.M., Xu B., Qiao S.B., Wu Y.J., Chen J., Wu Y., Chen J.L., Gao R.L., Yuan J.Q., Yang Y.J. Effect of the CYP2C19 2 and 3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention // Eur J Clin Pharmacol. – 2013. – Vol. 69. – No.5. – P. 1103–1112. DOI: 10.1007/s00228-012-1446-8.Yang J, Zhao HD, Tan J, Ding YL, Gu ZQ, Zou JJ. CYP2C19 polymorphism and antiplatelet effects of clopidogrel in Chinese stroke patients. Pharmazie. 2013 Mar;68(3):183–6.Yang J., Zhao H.D., Tan J., Ding Y.L., Gu Z.Q., Zou J.J. CYP2C19 polymorphism and antiplatelet effects of clopidogrel in Chinese stroke patients // Pharmazie. – 2013. – Vol. 68. – No.3. – P. 183–186.Tassaneeyakul W, Tawalee A, Tassaneeyakul W, Kukongviriyapan V, Blaisdell J, Goldstein JA, Gaysornsiri D. Analysis of the CYP2C19 polymorphism in a North-eastern Thai population. Pharmacogenetics. 2002 Apr;12(3):221–5. DOI: 10.1097/00008571-200204000-00006.Tassaneeyakul W, Tawalee A, Tassaneeyakul W, Kukongviriyapan V, Blaisdell J, Goldstein JA, Gaysornsiri D. Analysis of the CYP2C19 polymorphism in a North-eastern Thai population. Pharmacogenetics. 2002 Apr;12(3):221-5. DOI: 10.1097/00008571-200204000-00006.Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM, Stratz C, Schmiebusch P, Bestehorn HP, Büttner HJ, Neumann FJ. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol. 2008 May 20;51(20):1925-34. DOI: 10.1016/j.jacc.2007.12.056.Trenk D., Hochholzer W., Fromm M.F., Chialda L.E., Pahl A., Valina C.M., Stratz C., Schmiebusch P., Bestehorn H.P., Büttner H.J., Neumann F.J. Cytochrome P450 2C19681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents // J Am Coll Cardiol. – 2008. – Vol. 51. – No.20. – P. 1925–-1934. DOI: 10.1016/j.jacc.2007.12.056.Malek L.A., Kisiel B., Spiewak M., Grabowski M, Filipiak KJ, Kostrzewa G, Huczek Z, Ploski R, Opolski G. Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel. Circ J. 2008 Jul;72(7):1165–9. DOI: 10.1253/circj.72.1165.Malek L.A., Kisiel B., Spiewak M., Grabowski M, Filipiak KJ, Kostrzewa G, Huczek Z, Ploski R, Opolski G. Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel // Circ J. – 2008. – Vol. 72. – No.7. – P. 1165–1169. DOI: 10.1253/circj.72.1165.Giusti B, Gori AM, Marcucci R, Saracini C, Sestini I, Paniccia R, Buonamici P, Antoniucci D, Abbate R, Gensini GF. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol. 2009 Mar 15;103(6):806–11. DOI: 10.1016/j.amjcard.2008.11.048.Giusti B., Gori A.M., Marcucci R., Saracini C., Sestini I., Paniccia R., Buonamici P., Antoniucci D., Abbate R., Gensini G.F. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis // Am J Cardiol. – 2009. – Vol. 103. – No.6. – P. 806–811. DOI: 10.1016/j.amjcard.2008.11.048.Vicente J, González-Andrade F, Soriano A, Fanlo A, Martínez-Jarreta B, Sinués B. Genetic polymorphisms of CYP2C8, CYP2C9 and CYP2C19 in Ecuadorian Mestizo and Spaniard populations: a comparative study. Mol Biol Rep. 2014 Mar;41(3):1267–72. DOI: 10.1007/s11033-013-2971-y.Vicente J., González-Andrade F., Soriano A., Fanlo A., Martínez-Jarreta B., Sinués B. Genetic polymorphisms of CYP2C8, CYP2C9 and CYP2C19 in Ecuadorian Mestizo and Spaniard populations: a comparative study // Mol Biol Rep. – 2014. – Vol. 41. – No.3. – P. 1267–1272. DOI: 10.1007/s11033-013-2971-y.Jurima-Romet M, Goldstein JA, LeBelle M, Aubin RA, Foster BC, Walop W, Rode A. CYP2C19 genotyping and associated mephenytoin hydroxylation polymorphism in a Canadian Inuit population. Pharmacogenetics. 1996 Aug;6(4):329–39. DOI: 10.1097/00008571-199608000-00006.Jurima-Romet M., Goldstein J.A., LeBelle M., Aubin R.A., Foster B.C., Walop W., Rode A. CYP2C19 genotyping and associated mephenytoin hydroxylation polymorphism in a Canadian Inuit population // Pharmacogenetics. – 1996. – Vol. 6. – No.4. – P. 329–339. DOI: 10.1097/00008571-199608000-00006.Namazi S, Kojuri J, Khalili A, Azarpira N. The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients. Biochem Pharmacol. 2012 Apr 1;83(7):903–8. DOI: 10.1016/j.bcp.2012.01.003.Namazi S., Kojuri J., Khalili A., Azarpira N. The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients // Biochem Pharmacol. – 2012. – Vol. 83. – No.7. – P. 903–908. DOI: 10.1016/j.bcp.2012.01.003.Bozina N, Granić P, Lalić Z, Tramisak I, Lovrić M, Stavljenić-Rukavina A. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population. Croat Med J. 2003 Aug;44(4):425–8.Bozina N., Granić P., Lalić Z., Tramisak I., Lovrić M., Stavljenić-Rukavina A. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population // Croat Med J. – 2003. – Vol. 44. – No.4. – P. 425–428.Vargas-Alarcón G, Ramírez-Bello J, de la Peña A, Calderón-Cruz B, Peña-Duque MA, Martínez-Ríos MA, Ramírez-Fuentes S, Pérez-Méndez O, Fragoso JM. Distribution of ABCB1, CYP3A5, CYP2C19, and P2RY12 gene polymorphisms in a Mexican Mestizos population. Mol Biol Rep. 2014 Oct;41(10):7023–9. DOI: 10.1007/s11033-014-3590-y.Vargas-Alarcón G., Ramírez-Bello J., de la Peña A., Calderón-Cruz B., Peña-Duque M.A., Martínez-Ríos M.A., Ramírez-Fuentes S., Pérez-Méndez O., Fragoso J.M. Distribution of ABCB1, CYP3A5, CYP2C19, and P2RY12 gene polymorphisms in a Mexican Mestizos population // Mol Biol Rep. – 2014. – Vol. 41. – No.10. – P. 7023–7029. DOI: 10.1007/s11033-014-3590-y.Simon T, Steg PG, Gilard M, Blanchard D, Bonello L, Hanssen M, Lardoux H, Coste P, Lefèvre T, Drouet E, Mulak G, Bataille V, Ferrières J, Verstuyft C, Danchin N. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry. Circulation. 2011 Feb 8;123(5):474–82. DOI: 10.1161/CIRCULATIONAHA.110.965640.Huay-Cheem Tan, Mark Y., Chan M.Y., Tan K., Tan H.C et al. Functional significance and differential prevalence of CYP2C19 and PON1 polymorphisms regulating clopidogrelMirzaev KB, Zelenskaya EM, Barbarash OL, Ganyukov VI, Apartsin KA, Saraeva NO, Nikolaev KY, Ryzhikova KA, Lifshits GI, Sychev DA. CYP2C19 polymorphism frequency in Russian patients in Central Russia and Siberia with acute coronary syndrome. Pharmgenomics Pers Med. 2017 Apr 12;10:107–114. DOI: 10.2147/PGPM.S126305.bioactivation in сhinese, malay and indian subjects // Pharmacogenomics. – 2012. – No.13. – P. 533–542. DOI: 10.2217/pgs.12.24Rytkin EI, Mirzaev KB, Smirnov VV, Ryzhikova KA, Sozaeva ZhA, Andreev DA, Sychyov DA. Oslozhneniya chreskozhnogo koronarnogo vmeshatel’stva u pacientov s ostrym koronarnym sindromom: svyaz’ s polimorfizmami genov CYP2C19, ABCB1, CYP3A5 i aktivnost’yu izofermenta CYP3A4. Pharmacogenetics and Pharmacogenomics. 2017;2:26–26. RussianSimon T., Steg P.G., Gilard M., Blanchard D., Bonello L., Hanssen M., Lardoux H., Coste P., Lefèvre T., Drouet E., Mulak G., Bataille V., Ferrières J., Verstuyft C., Danchin N. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry // Circulation. – 2011. – Vol. 123. – No.5. – P. 474–482. DOI: 10.1161/CIRCULATIONAHA.110.965640.Goluhova EZ, Grigoryan MV, Ryabinina MN. The platelet reactivity after percutaneous coronary intervention in patients with double antiplatelet therapy: impact of genetic polymorphisms. Creative cardiology. 2013;2:15–27. RussianMirzaev K.B., Zelenskaya E.M., Barbarash O.L., Ganyukov V.I., Apartsin K.A., Saraeva N.O., Nikolaev K.Y., Ryzhikova K.A., Lifshits G.I., Sychev D.A. CYP2C19 polymorphism frequency in Russian patients in Central Russia and Siberia with acute coronary syndrome // Pharmgenomics Pers Med. – 2017. – No.10. – P. 107–114. DOI: 10.2147/PGPM.S126305.Komarov AL, Shakhmatova OO, Ilyushchenko TA, Donnikov AE, Dobrovolsky AB, Panchenko EP. Assessing Risk of Cardiovascular Events in Clopidogrel-Treated Patients with Stable CHD: Platelet Function or Genetic Testing? Kardiologiya; Doktor.ru. 2012;6(74):1–9. RussianРыткин Э.И., Мирзаев К.Б., Смирнов В.В., Рыжикова К.А., Созаева Ж.А., Андреев Д.А., Сычёв Д.А. Осложнения чрескожного коронарного вмешательства у пациентов с острым коронарным синдромом: связь с полиморфизмами генов CYP2C19, ABCB1, CYP3A5 и активностью изофермента CYP3A4 // Фармакогенетика и Фармакогеномика. – 2017. – №2. – С. 26–26.Knauer NYu, Lifshits GI, Voronina EN, et al. Informativeness of genetic factors for optimization of personalized therapy with clopidogrel. Kardiologiia 2013;8:72–5. RussianГолухова Е.З., Григорян М.В., Рябинина М.Н. Реактивность тромбоцитов на фоне двойной антиагрегантной терапии после стентирования коронарных артерий: генетический полиморфизм и клинические варианты // Креативная кардиология. – 2013. – Т. 7. – №2.Комаров А.Л., Шахматова О.О., Илющенко Т.А., Донников А.Е., Добровольский А.Б., Панченко Е.П. Оценка риска сердечно-сосудистых осложнений у больных стабильной ИБС, получающих клопидогрел: функция тромбоцитов или генетические исследования? // Кардиология; Доктор.ру. – 2012. – Т. 6. – №74. – С. 1–9.Кнауэр Н.Ю., Лифшиц Г.И., Воронина Е.Н., и др. Информативность генетических маркеров для оптимизации персонализированной терапии клопедогрелом // Кардиология. – 2013. – №8. – С. 72–75.